Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Other: 2019-2022

Historic Receivables - Other for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Dec 2022 value amounting to $700,000.

  • 4D Molecular Therapeutics' Receivables - Other changed negligibly% to $700,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $700,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $700,000 for FY2022, which is negligibly% changed negligibly from last year.
  • As of FY2022, 4D Molecular Therapeutics' Receivables - Other stood at $700,000, which was down 0.00% from $700,000 recorded in FY2021.
  • 4D Molecular Therapeutics' Receivables - Other's 5-year high stood at $700,000 during FY2021, with a 5-year trough of $149,000 in FY2019.
  • For the 2-year period, 4D Molecular Therapeutics' Receivables - Other averaged around $700,000, with its median value being $700,000 (2022).